Clinical trials
Completed Phase 1 trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
898 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 6 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 8 |
| 2005 | 17 |
| 2006 | 28 |
| 2007 | 32 |
| 2008 | 45 |
| 2009 | 58 |
| 2010 | 60 |
| 2011 | 82 |
| 2012 | 64 |
| 2013 | 50 |
| 2014 | 63 |
| 2015 | 59 |
| 2016 | 64 |
| 2017 | 48 |
| 2018 | 34 |
| 2019 | 33 |
| 2020 | 41 |
| 2021 | 32 |
| 2022 | 22 |
| 2023 | 14 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 898 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 76 |
| Novartis Pharmaceuticals | 51 |
| Boehringer Ingelheim | 28 |
| Sanofi | 28 |
| GlaxoSmithKline | 25 |
| AstraZeneca | 22 |
| Janssen Research & Development, LLC | 22 |
| Eli Lilly and Company | 21 |
| University Hospital, Clermont-Ferrand | 19 |
| Bristol-Myers Squibb | 17 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 114 |
| Carcinoma, Non-Small-Cell Lung | 43 |
| Breast Neoplasms | 38 |
| Neoplasm Metastasis | 32 |
| Multiple Myeloma | 29 |
| Melanoma | 28 |
| Leukemia, Myeloid, Acute | 27 |
| Lymphoma, Non-Hodgkin | 27 |
| Lymphoma | 19 |
| Carcinoma, Renal Cell | 18 |
Trials
Showing 1 to 25 of 898. Each trial links to its page on Pharma Observatory.
798 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.